• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    Achillion Pharmaceuticals, Inc. (ACHN)

    -NasdaqGS
    8.55 Down 0.25(2.84%) Apr 29, 4:00PM EDT
    ProfileGet Profile for:
    Achillion Pharmaceuticals, Inc.
    300 George Street
    New Haven, CT 06511
    United States - Map
    Phone: 203-624-7000
    Fax: 203-624-7003
    Website: http://www.achillion.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:79

    Business Summary 

    Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor, which has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor that is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and one additional systemic ultra-rare disease; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally; and license and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Achillion Pharmaceuticals, Inc.

    Corporate Governance 
    Achillion Pharmaceuticals, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Milind S. Deshpande Ph.D., 59
    Chief Exec. Officer, Pres and Director
    950.00K1.20M
    Ms. Mary Kay Fenton , 52
    Chief Financial Officer, Exec. VP and Sec.
    527.00K550.00K
    Mr. Joseph Truitt , 51
    Chief Commercial Officer and Exec. VP of Bus. Devel.
    543.00K0.00
    Dr. David Apelian M.D., Ph.D., MBA, 51
    Chief Medical Officer and Exec. VP
    702.00K74.00K
    Dr. Joel C. Barrish Ph.D.,
    Chief Scientific Officer and Exec. VP
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders